BRIEF-AstraZeneca says FALCON trial met its primary endpoint
December 08, 2016 at 08:43 AM EST
* AstraZeneca announces subgroup analysis from FALCON trial comparing Faslodex (fulvestrant) to Arimidex (anastrozole)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.